P SA (prostate-specific antigen) is an established tumor marker that aids in the diagnosis, staging, and follow-up of prostate cancer and which is expressed by both normal and neoplastic prostate tissue. PSA is also known as a member (human kallikrein gene 3) of the human kallikrein family of serine proteases, which is not specific to prostate, semen, and sex and with much remaining unknown about its function and forms.
Coronary artery calcium (CAC) scoring using computed tomography is a useful and reliable marker of coronary atherosclerosis. 10 CAC score reflects the long-term impact of elevated CVD risk factors and is an independent predictor for future CVD events across a wide range of ages, including asymptomatic young adults. 10, 11 Thus, measuring CAC can improve the understanding of the relationships between putative CVD risk factors and subclinical coronary artery atherosclerosis.
Epidemiological studies have shown that low testosterone is associated with increased CVD risk and CVD mortality, but its association with CVD risk remains controversial to date. [12] [13] [14] Until now, studies on the association between testosterone levels and subclinical coronary disease have been limited, with relatively small sample sizes. 15, 16 PSA is directly regulated by androgen, 17 and observational studies have shown a close relationship between testosterone and PSA levels, especially in young men. 18, 19 Indeed, low PSA has been proposed to be a marker of reduced bioactive testosterone, reflecting circulating levels of total testosterone, its active fractions, and androgen receptor transcriptional activity. 19 Therefore, we hypothesized that PSA level-a marker of bioactive androgen status-is associated with subclinical and clinical CVD.
The present study investigated the association of PSA level within the reference range with subclinical atherosclerosis as measured by CAC and the development of CVD mortality in a large sample of young and middle-aged asymptomatic men who participated in a health screening examination program.
Methods
The data and study materials will not be made available to other researchers for purposes of reproducing the results. However, analytical methods are available from the corresponding author on reasonable request.
Study Design and Participants
The Kangbuk Samsung Health Study is a cohort study of Korean men and women aged ≥18 years who underwent a comprehensive annual or biennial health examination at the Kangbuk Samsung Hospital Total Healthcare Centers in Seoul and Suwon, South Korea. 20, 21 More than 80% of participants were employees of various companies and local governmental organizations and their spouses. In South Korea, the Industrial Safety and Health Law requires annual or biennial health screening exams of all employees, offered free of charge. The remaining participants voluntarily paid for screening examinations at the health screening center. This study was designed to use data routinely collected as part of health screening examinations where questionnaires, blood tests, imaging examination, and procedures (eg, ultrasound, endoscopy) are components of health screening exams. 20, 21 The number of participants enrolled during the study period determined the sample size.
PSA Level and Prevalent CAC: a Cross-Sectional Study
For the analysis of an association between PSA level and subclinical atherosclerosis, the study population consisted of the subset of male Kangbuk Samsung Health Study participants who underwent a cardiac computed tomographic scan to measure CAC score as part of a comprehensive health exam between 2011 and 2017 (n=92 998). CAC scoring has become a common CVD screening test in Korea. 21 A total of 4795 subjects who met the following criteria were excluded: missing information on PSA level (n=32); history of CVD (n=1154); history of prostate cancer or bladder cancer (n=95); surgical history of prostate (n=73); use of medication for benign prostatic hyperplasia (BPH), male sex hormone, or finasteride (n=2048); PSA level of ≥4 ng/mL (n=938); and a history of liver cirrhosis or findings of liver cirrhosis on ultrasound (n=55). Some participants met >1 of the exclusion criteria. Finally, 88 203 participants were included in the analysis (Figure 1 ). What New Information Does This Article Contribute?
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• Serum total PSA levels within the reference range were inversely associated with subclinical atherosclerosis and CVD mortality in young and middle-aged Korean men.
In this cohort study of apparently healthy young and middle-aged Korean men, serum total PSA levels within the reference range were inversely associated with CVD mortality. After further adjustment for possible confounders and established cardiovascular risk factors, a significant association between PSA and CVD mortality was still observed. Serum PSA levels within the reference range were also independently associated with an increased presence of coronary artery calcification. Our study findings indicate that serum total PSA levels within the reference range may predict subclinical and clinical CVD. Future studies are needed to elucidate the mechanism underlying the interrelationships between PSA, androgen activity, and CVD and to examine whether measurement of serum PSA may help identify individuals at high risk of CVD. May 10, 2019
PSA Level and Risk for CVD Mortality: a Cohort Study
For the analysis of the association of PSA level and the development of CVD mortality, the study population consisted of male examinees who participated in a comprehensive health screening exam between 2002 and 2014 (n=263 399). We excluded 16 501 subjects for the following reasons at baseline, in addition to unknown vital status (n=1; Figure 2 ): missing information on PSA level (n=3403); history of CVD (n=9513); history of prostate cancer or bladder cancer (n=91); history of prostate surgery (n=574); use of medication for BPH, male sex hormone, or finasteride (n=3758); PSA level of ≥4 ng/mL (n=3071); and a history of liver cirrhosis or findings of liver cirrhosis on ultrasound (n=173). Some participants met >1 exclusion criterion, leaving a final sample size of 243 435 male participants. This study was approved by the Institutional Review Board of Kangbuk Samsung Hospital (KBSMC 2018-03-018). The requirement for informed consent was waived because of the use of deidentified data obtained as part of routine health screening exams.
Measurements
Demographic characteristics, health behaviors, medical history, and medication use were collected as part of the baseline health examinations by standardized, self-administered questionnaires, as described previously. 20 Smoking status was classified as never, former, and current smoking habits. Alcohol consumption was categorized as either ≤20 or >20 g/d. The weekly frequency of moderate or vigorous physical activity was also assessed. Physical activity levels were determined using the validated Korean version of the International Physical Activity Questionnaire short form. 22, 23 Physical activity levels were classified into 3 categories: inactive, minimally active, and health-enhancing physically active.
24 Health-enhancing physically active was defined as physical activity that meets either of the 2 criteria: (1) vigorous-intensity activity on ≥3 days per week accumulating ≥1500 metabolic equivalent minutes per week (1 metabolic equivalent is energy expenditure at rest) or (2) 7 days of any combination of walking, moderate-intensity activities, or vigorous-intensity activities achieving at least 3000 metabolic equivalent minutes per week. 23 Usual dietary consumption during the past year was assessed using a 106-item self-administered food frequency questionnaire designed and validated for use in Korea. 25 Height, weight, and blood pressure were measured by trained nurses. Obesity was defined as a body mass index (BMI) ≥25 kg/m 2 according to Asian-specific criteria. 26 Hypertension was defined as a systolic blood pressure of ≥140 mm Hg, a diastolic blood pressure of ≥90 mm Hg, or the current use of antihypertensive medications.
Blood specimens were obtained after at least a 10-hour fast. Serum levels of glucose, insulin, total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), ALT (alanine aminotransferase), and hsCRP (high-sensitivity C-reactive protein) were measured as previously described in detail. 21 Insulin resistance was assessed with the HOMA-IR (homeostasis model assessment of insulin resistance) equation, as follows: fasting blood insulin (uU/mL)×fasting blood glucose (mmol/L)/22.5. Diabetes mellitus was defined as a fasting serum glucose level of ≥126 mg/dL, an A1c level of ≥6.5%, or the current use of insulin or antidiabetic medications. Serum PSA levels were measured on the day of blood collection by immunoradiometric assay using an ELSA-PSA2 kit (CIS Bio International, Gif-sur-Yvette, France) between 2002 and 2009 and thereafter by way of an electrochemiluminescence immunoassay with the Modular E170 system (Roche Diagnostics, Tokyo, Japan). Metabolic syndrome (MetS) was defined using the following harmonized criteria 27 : (1) abdominal obesity, (2) fasting blood glucose ≥100 mg/d or current use of blood glucose-lowering agents, (3) blood pressure ≥130/85 mm Hg or current use of blood pressurelowering agents, (4) triglyceride levels ≥150 mg/dL or current use of lipid-lowering agents, and (5) HDL-C <40 mg/dL in men. Because waist circumference measurements were not available for all subjects, we substituted overall adiposity (ie, BMI ≥25 kg/m 2 , which has been proposed as a cutoff for the diagnosis of obesity in Asians 26 ) for abdominal obesity.
The diagnosis of fatty liver was based on abdominal ultrasound operated by experienced radiologists who were blinded to the aim of the present study. Ultrasonographic diagnosis of fatty liver was determined based on known standard criteria, including the presence of a diffuse increase of fine echoes in the liver parenchyma as compared with kidney or spleen parenchyma, deep beam attenuation, and bright vessel walls. 
Measurement of CAC by Multidetector Computed Tomography
CAC was detected with a Lightspeed VCT XTe-64 slice MDCT scanner (GE Healthcare, Tokyo, Japan) in both the Seoul and Suwon centers using the same standard scanning protocol of a 2.5-mm thickness, 400-ms rotation time, 120-kV tube voltage, and 124-mAS (310 mA×0.4 s) tube current under ECG-gated dose modulation. 21 CAC scores were calculated as previously described by Agatston et al. 29 Interobserver reliability and intraobserver reliability for CAC scores were both excellent (intraclass correlation coefficient of 0.99). 21 CAC scores were categorized into categories of 0, 1 to 100, and >100 points.
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Mortality Follow-Up
Mortality follow-up until the end of 2015 was based on nationwide death certificate data from the Korea National Statistical Office. Death certificate data for Korean adults are virtually complete because all deaths of Koreans are reported to the Korea National Statistical Office. We determined the cause of death using the underlying cause listed on each death certificate, as classified according to the International Classification of Diseases and Related Health Problems, Tenth Revision. Concordance between the cause of death on the death certificate and patient diagnosis in the medical utilization data was 72.2% for all-cause deaths. 31 CVD mortality was defined as International Classification of Diseases, Tenth Revision, codes I00 to I99.
Statistical Analysis
Descriptive statistics were used to summarize the characteristics of participants by PSA quartile. Serum total PSA levels were categorized into the quartiles within the reference range based on distribution within the study population. The distribution of continuous variables was evaluated, and right-skewed variables (ie, triglycerides, alanine aminotransferase, hsCRP, and HOMA-IR) were log-transformed for 1-way ANOVA. To test for linear trends, we included the median value of each PSA category as a continuous variable in the regression models.
PSA Level and Prevalent CAC: a Cross-Sectional Study
For the cross-sectional analysis of the association between PSA level and CAC, the PSA first to fourth quartiles were <0.58, 0.58 to 0.80, 0.81 to 1.13, and 1.14 to 3.99 ng/mL, respectively, based on distribution within the study population for cross-sectional study. To assess the relationship of the presence of CAC with PSA categories, a logistic regression model was used to estimate the odds ratio (OR) with a 95% CI for the presence of CAC comparing PSA quartiles 2, 3, and 4 to the lowest quartile. The models were initially adjusted for age and then for center, year of screening examination, smoking status, alcohol intake, physical activity, educational level, total calorie intake, history of hypertension, and family history of CVD. An additional model was further adjusted for medication for hyperlipidemia, HDL-C, LDL-C, triglycerides, glucose, HOMA-IR, and hsCRP. To determine linear trends of prevalence, the median PSA value of each PSA category was included in the model.
Additionally, we assumed that CAC scores followed a log-normal distribution with left-censored values at 0 AU (nondetectable CAC score). To evaluate the association between PSA quartiles and CAC, we used a Tobit regression model for natural log (CAC score +1) with Huber-White estimation of the SEs. 32, 33 Tobit models were used to estimate ratios and 95% CIs of CAC score +1, comparing PSA quartiles 2, 3, and 4 to the lowest quartile. We presented estimates of the Tobit models as exponentiated Tobit regression coefficients (CAC score ratios), approximately representing the relative CAC score increment comparing the second through the fourth quartiles of PSA with the lowest (first) quartile. For example, a CAC ratio of 0.50 can be interpreted as a 50% decrease in CAC score for the specific quartile in question as compared with the lowest quartile. As secondary analyses, we also estimated prevalence ratios and 95% CIs for the CAC score groups of 1 to 100 and >100 points, respectively, for PSA quartiles 2, 3, and 4 in comparison with the first quartile using participants with a CAC score of 0 points as the reference group in multinomial logistic regression models.
A subgroup analysis was conducted according to age group (<40 versus ≥40 years). Interactions according to subgroup were tested using likelihood ratio tests, comparing models with and without multiplicative interaction terms. To further explore the shape of the dose-response relationship of PSA level with CAC stratified by age group (<40 versus ≥40 years), restricted cubic splines with knots were used at the 5th, 27.5th, 50th, 72.5th, and 95th percentiles of PSA distribution.
PSA Level and Risk for CVD Mortality: a Cohort Study
For the longitudinal cohort analysis of the association between PSA level and CVD mortality, PSA quartile levels (ng/mL) were the following: for electrochemiluminescence immunoassay, quartile 1, <0.60 ng/mL; quartile 2, 0.60 to 0.81 ng/mL; quartile 3, 0.82 to 1.16 ng/mL; and quartile 4, 1.17 to 4.00 ng/mL. Additionally, for immunoradiometric assay, the cutoffs for the quartiles were as follows: quartile 1, <0.70 ng/mL; quartile 2, 0.70 to 0.92 ng/mL; quartile 3, 0.93 to 1.26 ng/mL; and quartile 4, 1.27 to 4.00 ng/mL.
The primary end point was development of CVD mortality. Each participant was followed from the baseline exam until either the development of CVD mortality or the end of 2015, whichever came first. Participants who died of other causes were censored at the date of death. Hazard ratios and 95% CIs for CVD mortality were estimated using Cox proportional hazards regression analyses. Age was used as the timescale, which was documented by the age at which subjects underwent their first health checkup exam (left truncation) and the age at which subjects exited the analysis at the date of death or on December 31, 2015. This approach effectively controls for age in the analysis. The proportional hazards assumption was assessed by examining graphs of estimated log(−log[survival]); no violation of the assumption was found.
Models were initially adjusted for age (as the timescale) and then were further adjusted for study center (Seoul or Suwon), year of screening exam (1-year categories), smoking (never, past, current, or unknown), alcohol intake (0, <20, or ≥20 g/d or unknown), regular exercise (<3× a week, ≥3× a week, or unknown), BMI (continuous), education level (less than community college graduate, community college graduate or higher, or unknown), history of hypertension, history of diabetes mellitus, and family history of CVD. Finally, model 3 was further adjusted for medication for hyperlipidemia, HDL-C, LDL-C, triglyceride, glucose, HOMA-IR, and hsCRP.
Statistical analysis was performed using the STATA, version 15.0, software (StataCorp LP, College Station, TX). All reported P values were 2 tailed, with P <0.05 considered to be statistically significant.
Results
Cross-Sectional Study on the Association Between PSA Level and Prevalent CAC
The mean age (SD) and mean BMI (SD) of the 88 203 participants were 40.9 years (7.6) and 25.0 kg/m 2 (3.1), respectively ( Table 1 ). The median (interquartile range) PSA level was 0.81 ng/mL (0.58-1.14). PSA level was positively associated with age, current smoking, and HDL-C and negatively associated with obesity, physical activity, diabetes mellitus, fatty liver, LDL-C, triglyceride, and HOMA-IR. The prevalence of a CAC score of >0 points was 15.1% overall. Table 2 shows the relationship between PSA quartiles and the presence of detectable CAC (>0). PSA level was inversely associated with the presence of CAC. After adjustment for age, screening center, year of screening examination, smoking status, alcohol intake, physical activity, educational level, total calorie intake, BMI, history of hypertension, and family history of CVD (Table 2 , model 2), multivariable-adjusted OR (95% CIs) for detectable CAC comparing PSA quartiles 2, 3, and 4 to the lowest quartile were 0.96 (0.90-1.01), 0.88 Data are presented as mean (SD), median (interquartile range), or percentage. BMI indicates body mass index; BP, blood pressure; CAC, coronary artery calcium; CVD, cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; HEPA, health-enhancing physically active; HOMA-IR, homeostasis model assessment of insulin resistance; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; MetS, metabolic syndrome; and PSA, prostate-specific antigen.
*Mean (SD). †≥20 g of ethanol per day. ‡College graduate or higher. §Median (interquartile range). ‖Among 56 312 participants with plausible estimated energy intake levels (within 3 SDs from the log-transformed mean energy intake). BMI indicates body mass index; CAC, coronary artery calcium; CVD, cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; OR, odds ratio; and PSA, prostate-specific antigen.
*Per 100 persons indicate age-adjusted prevalence per 100 persons. †Estimated from binomial logistic regression models used with prevalent CAC >0 as the outcome. Model 1 was adjusted for age; model 2 was further adjusted for center, year of screening examination, BMI, smoking status, alcohol intake, physical activity, educational level, total calorie intake, history of hypertension, history of diabetes mellitus, and family history of CVD; model 3 was further adjusted for medication for hyperlipidemia, HDL-C, LDL-C, triglyceride, glucose, HOMA-IR, and hsCRP. BMI indicates body mass index; CAC, coronary artery calcium; CVD, cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; PR, prevalence ratio; and PSA, prostatespecific antigen. *Per 100 persons indicate age-adjusted prevalence per 100 persons. †Estimated from multinomial logistic regression models using CAC scores as outcomes categorized as 0, 1 to 100, and >100. Multivariable model 1 was adjusted for age; model 2 was further adjusted for center, year of screening examination, BMI, smoking status, alcohol intake, physical activity, educational level, total calorie intake, history of hypertension, history of diabetes mellitus, and family history of CVD; model 3: model 2 further adjusted for medication for hyperlipidemia, HDL-C, LDL-C, triglyceride, glucose, HOMA-IR, and hsCRP.
Similar findings were additionally observed in multinomial regression models with categorized CAC scores as outcomes (Table 3) . Specifically, the multivariable-adjusted prevalence ratios comparing PSA quartiles 2, 3, and 4 to the lowest quartile were 0.95 (0.90-1.01), 0.88 (0.83-0.93), and 0.85 (0.80-0.90) for the CAC score range of 1 point to 100 points and 0.98 (0.86-1.11), 0.87 (0.77-1.00), and 0.84 (0.74-0.95) for the CAC score range of >100 points, respectively (Table 4 , model 2). After further adjusting for hyperlipidemia medication, LDL-C, HDL-C, triglycerides, glucose, HOMR-IR, and hsCRP, the findings were similar (Table 3 , model 3). In sensitivity analysis using Tobit regression model, multivariable-adjusted CAC score ratios (95% CIs) comparing PSA quartiles 2, 3, and 4 to the lowest quartile were 0.90 (0.80-1.02), 0.76 (0.67-0.86), and 0.69 (0.61-0.79), respectively (Online Table  I ). After the exclusion of 1531 participants with a history of malignancy (Online Table II) , the results obtained were similar to those of the original analysis.
The association was stronger in younger individuals (age <40 years; P for interaction, 0.002; Online Table III ). In spline regression analyses, there was a linearly inverse association between serum PSA level and CAC score among men <40 years, whereas a reverse J shape was observed in men who were ≥40 years of age (Figure 3 ; Online Figure I ).
Cohort Study on the Association Between PSA Level and Risk for CVD Mortality
At baseline, the mean age (SD) and mean BMI (SD) of study participants were 39.3 (9.7) years and 24.4 (2.9) kg/m 2 , respectively ( Table 4 ). The median (interquartile range) PSA levels were 0.81 ng/mL (0.60-1.16) for those measured by electrochemiluminescence immunoassay and 0.92 ng/mL (0.70-1.26) for those measured by immunoradiometric assay. PSA level was positively associated with age and HDL-C and negatively associated with obesity, diabetes mellitus, fatty liver, total cholesterol, LDL-C, triglyceride, and HOMA-IR.
During 1 829 070.1 person-years of follow-up, 336 participants died from CVD. Median duration of follow-up was 7.3 years (interquartile range, 3.9-11.4 years; maximum, 14 years). After adjustment for age (as the timescale), study center, year ≥40 y [B] ). Curves represent adjusted CAC score ratios based on restricted cubic splines with knots at the 5th, 27.5th, 50th, 72.5th, and 95th percentiles of PSA distribution. Models were adjusted for age, center, year of screening examination, body mass index, smoking status, alcohol intake, physical activity, educational level, total calorie intake, history of hypertension, and family history of cardiovascular disease.
of screening examination, BMI, smoking status, alcohol intake, physical activity, educational level, history of hypertension, history of diabetes mellitus, and family history of CVD (Table 5, (Table 5) . After the exclusion of 2344 participants with a history of malignancy (Online Table I ), the multivariable-adjusted hazard ratios (95% CI) for CVD mortality comparing PSA quartiles 2, 3, and 4 to the lowest quartile were 0.90 (0.67-1.22), 0.78 (0.57-1.07), and 0.68 (0.50-0.92), respectively.
Discussion
In this large-scale cohort study of ostensibly healthy Korean men participating in health screening exams, PSA levels within the reference range were inversely associated with Data are presented as mean (SD), median (interquartile range), or percentage. PSA quartile levels (ng/mL). Electrochemiluminescence immunoassay: quartile 1, <0.60; quartile 2, 0.60 to 0.81; quartile 3, 0.82 to 1.16; and quartile 4, 1.17 to 4.00. Immunoradiometric assay: quartile 1, <0.70; quartile 2, 0.70 to 0.92; quartile 3, 0.93 to 1.26; and quartile 4, 1.27 to 4.00. BMI indicates body mass index; BP, blood pressure; CVD, cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; MetS, metabolic syndrome; and PSA, prostate-specific antigen.
*Mean (SD). †≥20 g of ethanol per day. ‡≥3× per week. §College graduate or higher. ‖Median (interquartile range).
subclinical coronary atherosclerosis measured by CAC and CVD mortality in a dose-response manner. These associations were still observed after the adjustment for potential confounders including traditional CVD risk factors. Our findings suggest a role of PSA as an independent predictive marker for both subclinical and clinical CVD. PSA is well-known for its use as a tumor marker in patients with prostate cancer, but recent studies have also indicated that serum PSA is associated with nonprostate conditions such as obesity, diabetes mellitus, hypertension, MetS, and CVD. [2] [3] [4] [5] [6] [7] 9, 34, 35 Regarding the association between PSA and CVD, several cross-sectional studies have explored the potential connection. 2, 19, 35 A retrospective chart review study of 140 elderly men aged 65 to 80 years reported that those with low PSA levels of <1 ng/mL were less likely to have coronary artery disease as compared with those with higher serum PSA levels. 35 However, this study was limited by its cross-sectional design, small sample size, and lack of adjustment for confounders. On the contrary, a later study of 2967 patients seeking medical care for sexual dysfunction who demonstrated a mean age of 52.5 years (SD, 12.4; range, 18-85 years) reported that low PSA level defined as <0.65 ng/ mL was associated with a higher prevalence of CVD history (age-adjusted OR, 1.207) and MetS (age-adjusted OR, 1.506) in relation to testosterone deficiency. 19 In the current cohort study of young and middle-aged men without known CVD or prostate disease, serum PSA within the reference range was significantly and inversely associated with CAC scores in a dose-response manner. Our findings are in line with those of previous cross-sectional studies showing an inverse association between testosterone and preclinical atherosclerosis measured by carotid intima-media thickness or CAC. 15, 16 Furthermore, in the present cohort study, higher levels of serum PSA within the reference range at baseline were associated with a decreased risk for CVD mortality. Previous epidemiological studies and meta-analysis have demonstrated the association of endogenous testosterone deficiency or low serum testosterone with an increased risk for atherosclerosis, CVD events, or CVD mortality. 14, [36] [37] [38] A recent meta-analysis of observational studies reported that low endogenous testosterone at enrollment predicted overall and CVD mortality and CVD morbidity (fully adjusted OR, 1.26 [95% CI, 1.17-1.36] for overall mortality; 1.54 [95% CI, 1.25-1.89] for CVD mortality; and 1.17 [95% CI, 1.01-1.36] for CVD incidence). 39 However, many of these studies were performed in elderly people or patients in the hospital setting, raising uncertainty as to whether an observed association is a causal relationship or because of low testosterone levels being a marker of poor overall health.
14,36-38 In contrast, our study participants were mostly asymptomatic, healthy employees and their spouses without . BMI indicates body mass index; CVD, cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; HR, hazard ratio; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; and PSA, prostate-specific antigen.
*Cox proportional hazard models using age as a timescale were used to estimate HRs and 95% CIs; model 1 was adjusted for age (timescale); model 2 was further adjusted for center, year of screening examination, BMI, smoking status, alcohol intake, physical activity, educational level, history of hypertension, history of diabetes mellitus, and family history of CVD; model 3 was model 1 further adjusted for medication for hyperlipidemia, HDL-C, LDL-C, triglyceride, glucose, HOMA-IR, and hsCRP.
known CVD or prostate disease who underwent health checkups that included serum PSA measurement as a routine part of the screening. Thus, our cohort was less likely to be affected by patient selection bias or by biases related to comorbidities in comparison with prior studies involving higher risk or older populations.
The mechanisms underlying the association between serum PSA level and subclinical atherosclerosis or CVD mortality remain incompletely understood. To date, several studies have reported positive association between testosterone and serum PSA concentration (correlation coefficient, 0.064-0.354). 18, 19, 40 Especially in an environment of relatively low androgenicity such as subfertile men with defective spermatogenesis, the correlation between testosterone and PSA was pronounced, with corresponding correlation coefficient of 0.354, and short AR (androgen receptor) gene CAG (cytosine, adenine, guanine) repeat length (associated with high AR activity) also correlated positively with PSA concentration. 40 In a nationally representative sample of the US population without a diagnosis of prostate cancer, geometric mean PSA increased across testosterone quintile after adjustment for age and race/ethnicity (Q1, 0.80; Q5, 1.14 ng/mL; P trend, 0.002); and patterns were similar for free testosterone and androstanediol glucuronide. 41 A systematic review of studies on testosterone replacement therapy in hypogonadal men demonstrated an average increase in serum PSA level of about 0.3 ng/mL. 42 Similarly, a recent meta-analysis of randomized controlled trials also demonstrated that intramuscular preparations of testosterone replacement treatment were associated with increase in serum PSA with difference in means of PSA level of 0.271 ng/mL (95% CI, 0.117-0.425). 43, 44 Indeed, PSA is directly regulated by androgen, 17 and studies have shown a possible role of low PSA level as a predictor of testosterone deficiency. 18, 19 As PSA levels might reflect the biological activity of testosterone at the level of the prostate, one main androgen target tissue, PSA levels can be a marker of reduced bioactive testosterone or androgen receptor stimulation. 19 However, the association between testosterone and PSA appears to be nonlinear and supports a saturation model, with data indicating that serum PSA increases with increasing serum testosterone until the concentration reaches ≈8 nmol/L, at which point a plateau may occur with no further increase in serum PSA even at the higher serum testosterone concentrations. 45, 46 Previous studies have also suggested a predictive role of PSA as a marker of testosterone deficiency, although there are no established reference ranges relating PSA level to hypogonadal status. 47 In a study of 2291 patients sourced from an outpatient clinic and being treated for sexual dysfunction, patients with higher PSA levels had a lower prevalence of hypogonadism-related symptoms and signs, as well as higher levels of total testosterone and calculated free testosterone. 18 Another study of 2967 patients attending the clinic for sexual dysfunction has demonstrated that the receiver operating characteristic curve of PSA was 0.612±0.022 for predicting hypogonadism (total testosterone, <8 nmol/L), with the best sensitivity and specificity at PSA <0.65 ng/mL (65.2% and 55.5%, respectively). 19 In the same study, low PSA level was associated with hypogonadism features and hypogonadismrelated conditions including MetS, diabetes mellitus, and CVD, 19 and these associations were still observed even after adjustment for testosterone level, possibly suggesting that low PSA level could be a marker of hypogonadism-related conditions that might not be captured by testosterone. Androgen deficiency is commonly related with CVD risk factors, including obesity, hypertension, dyslipidemia, and diabetes mellitus. 14, [48] [49] [50] Similarly, recent studies also revealed a significant relationship between PSA and metabolic diseases such as diabetes mellitus and MetS, 5, 6, 51 which are closely related with atherosclerotic CVD. In our study, the inverse association of serum PSA level with CAC score and CVD mortality remained after adjustment for possible confounders and metabolic parameters including glucose, LDL-C, HDL-C, triglycerides, HOMA-IR, and hsCRP, indicating that those CVD risk factors did not fully explain the association between PSA and CVD. A body of evidence suggests that androgens exhibit beneficial effects on cardiovascular function through multiple biological mechanisms including the modulation of endothelial functions by androgens, the enhancement of vasodilation, the reduction of myocardial infarct size, and the improvement of lipid metabolism, but there are also studies that have suggested the deleterious effects of testosterone on the cardiovascular system. 12, 38, 52 Further research involving the actual measurement of testosterone and other sex hormones is needed to elucidate the mechanisms underlying the relationships between PSA, androgen activity, and CVD.
In this study, the inverse association between serum PSA levels, within the normal range, and CAC was more evident in men aged <40 years than in older men. Given that the prevalence rate of BPH or other prostatic diseases starts to increase from the age of 40 years and most of guidelines recommend the performance of a routine screening or examination for BPH from this age onward, 53 subgroup analyses stratified by the age of 40 years (ie, <40 versus ≥40 years) were performed because PSA might also reflect BPH or other prostatic diseases. In men aged <40 years, increasing PSA levels were linearly and progressively associated with decreased CAC, whereas in men aged ≥40 years, a reverse J shape between serum PSA levels and CAC scores was observed. Rastelli et al 19 reported that the accuracy of a low PSA level as a biomarker for detecting low androgen status is attenuated in the elderly population, suggesting that the accuracy of PSA level in detecting hypogonadism decreases as a function of age. Similarly, Corona et al 18 noted a significant relationship between total testosterone and PSA level in only the younger population. The primary reason for the inconsistent relationship between serum PSA and testosterone level can be explained by this age-related factor, which could be attributed to various factors on PSA level, including prostate cancer, inflammation, and BPH. 18, 54, 55 In older groups, low serum PSA level may reflect a low androgen status; however, those men with normal or high PSA levels in the older groups should not be ruled out as having other pathological conditions. Most studies included relatively older populations, which could attenuate the association between PSA and testosterone level. In our study, the study population was relatively much younger with a mean age of 39.3 (SD, 9.6) years as compared with prior studies, enabling us to find a moderate association of PSA level with subclinical atherosclerosis and CVD mortality.
Several limitations of our study need to be considered. First, the cross-sectional design precluded the temporal relationship between PSA level and CAC score. However, our study population included asymptomatic, apparently healthy and relatively young individuals without clinically manifest CVD, thus minimizing the possibility of reverse causation between PSA level and subclinical atherosclerosis. Furthermore, the inverse association between serum PSA and incident CVD mortality was consistently observed in the cohort study. Second, although this study excluded patients with a self-reported diagnosis of prostate cancer or prostate disease and with PSA levels of ≥4 ng/mL, patients with prostate cancer could have been included in the analysis. However, prostate cancer risk increases with age, and its prevalence is rare under the age of 40 years. 56 Thus, the accidental inclusion of patients with prostate cancer is unlikely to explain the association between PSA and subclinical and clinical CVD observed in our study. Third, data on prostate volume, testosterone, and hypogonadism features were not available, limiting our ability to examine the association between PSA and CAC score or CVD mortality while considering prostate volume, testosterone, and hypogonadism features. Fourth, serum PSA level was determined on a single, fasting blood measurement. Unlike testosterone, which has a diurnal variation, the variations of PSA level appear to be random, without any discernable diurnal or circadian pattern. [57] [58] [59] A single measure of serum PSA in our study may have resulted in random measurement error, possibly underestimating the true association between PSA and CVD. Furthermore, we cannot exclude the possibility of some unmeasured factors or residual confounding in relation to the association of PSA with CVD. Finally, the study population consisted of young and middle-aged Korean men who regularly attended health screening exams. Therefore, our findings may not be generalizable to other age groups, to populations with a higher prevalence of comorbidities, or to other race/ethnicity groups.
The strengths of our study include its large sample size; the use of carefully standardized and high-quality clinical images and procedures; and the availability of an extensive panel of health-related variables, risk factors, and morbidity. These factors enabled the adjustment of possible confounders to identify the association between serum PSA levels and asymptomatic subclinical CVD, as well as CVD mortality.
In conclusion, our study demonstrated the independent and inverse association of PSA level within the normal range with subclinical atherosclerosis and CVD mortality in a large sample of young and middle-aged Korean men. This study suggests that lower PSA levels within the normal range can be a nontraditional risk marker of subclinical atherosclerosis and CVD mortality. Further research is needed to elucidate the mechanisms underlying the relationships between PSA, androgen activity, and CVD.
